Autonomix Medical Reports Positive Results In First Human Trial For Cancer Pain, Stock Down

(RTTNews) - Autonomix Medical, Inc. (AMIX), Wednesday announced encouraging results from the first phase of its human proof-of-concept trial assessing a novel nerve-targeting procedure to relieve pain in patients with advanced pancreatic cancer.

The trial enrolled 20 patients, with 19 successfully treated using transvascular energy delivered via catheter. Significant pain relief was observed as early as 24 hours post-procedure, with improvements sustained through 4-6 weeks.

Notably, patients accessing treatment via the femoral artery showed a 59.2 percent average pain reduction and reported enhanced quality of life and reduced opioid use. No serious device-related adverse events were reported.

These promising findings have led Autonomix to expand its study into a PoC 2 phase, targeting additional visceral cancers and earlier-stage pancreatic cancer.

AMIX is currently trading at $2.22, down $0.30 or 11.86 percent on the Nasdaq.